基因组分析公司Bionano Genomics（BNGO）今日盘前股价大涨24.06%，主要受益于公司发布的2025年第一季度财报好于市场预期。
根据公司公布的财报，Bionano Genomics第一季度调整后每股亏损1.15美元，远低于分析师平均预期的亏损3.02美元。公司营收为646万美元，虽同比下降26.4%，但仍高于分析师预期的623万美元。这一业绩表现显示出公司在控制成本和提高运营效率方面取得了显著进展。
值得注意的是，Bionano Genomics股价在过去一个季度上涨了34.1%，但今年迄今为止仍下跌了78.4%。分析师对该公司的平均评级为"持有"，12个月目标价中位数为7.00美元。这次超预期的财报可能会提振投资者信心，但考虑到公司仍处于亏损状态，投资者可能需要关注公司未来的增长策略和盈利前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.